Topical Ruxolitinib Evaluation in Chronic Hand Eczema

Prior treatment

• Known triggers for CHE (allergic or irritant, such as those identified by previous patch tests) cannot be avoided during the course of this study.
• Use of protocol-defined treatments within the indicated washout period before baseline.
• Psoralen ultraviolet A (PUVA) or ultraviolet B (UVB) therapy on the hands within 4 weeks before baseline.

Other illness

• Any serious illness or medical, physical, or psychiatric condition(s).

Lab values

• Laboratory values outside of the protocol-defined criteria.

Other

• Pregnant or lactating participants, or those considering pregnancy during the period of their study participation.
  • Other protocol-defined Inclusion/Exclusion Criteria may apply.

• Diagnosis of CHE for at least 6 months prior to screening. Diagnosis of chromic hand eczema (CHE) as defined by hand eczema (HE) lasting \> 3 months or ≥ 2 flares within the previous 12 months.
• Screening and baseline IGA-CHE 3 or 4.
• Baseline CHE-related Itch NRS ≥ 4.
• Have been treated with at least 1 prescription CHE therapy or if such therapy was not advisable or contraindicated.
• Willingness to avoid pregnancy or fathering children based on the criteria defined in the protocol.